Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ACAD)

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

Business Wire 2 hours ago

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Business Wire 2 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 5 days ago

Acadia Pharmaceuticals Presents New DAYBUE(TM) (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

Business Wire 7 days ago

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire April 5, 2024

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Business Wire April 2, 2024

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 1, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire April 1, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 28, 2024
View More News ››

Opinion & Analysis (NDAQ:ACAD)

Embrace low-cap biotech for high gains: Eden Rahim of Next Edge Capital

The Life Sciences Report March 2, 2016

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

The Calandra Report: Watch this hot tub!

Thom Calandra January 10, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ACAD)

ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA A

$ACAD Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central...
AviseAnalytics - June 22, 2022

FDA Approves ACADIA Pharmaceuticals - Parkinson's Disease

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative...
DaveInCalgary - April 30, 2016

RE:RE: Long Term Hold?

Their PD product, pimavanserin, is on an expedited path to an NDA filing and their balance sheet is looking good. Great potential. Very...
captcanuck - August 9, 2013

RE: Long Term Hold?

That's a heavy blow to have discover the product is no better than what is already out there, or more importantly no different. If...
amy89 - June 21, 2008

RE: Long Term Hold?

Although it has the ability to tap into the aging baby-boomers market, it has to get to the market first. Its schizophrenia drug had...
gossipgirl - June 20, 2008

RE: Long Term Hold?

For long term, i would def. consider this stock a buy! Like you mentioned, the baby boom era def. benefits this company I also like that...
vforvalue - June 20, 2008
View more Bullboard ››

World Copper Ltd

World Copper Ltd

World Copper Ltd. is a Canada-based exploration stage junior mining company, which is engaged in the identification ...
View More »